Moderna’s $2.25B Patent Settlement Spurs 10% After-Hours Rally, Cuts Cash Cushion
Moderna agreed to pay up to $2.25B (including a $950M upfront payment) to settle COVID vaccine patent claims, spurring a 10% after-hours rally. The deal narrows its liquidity cushion after a $1.873B operating cash burn in FY2025 and trims projected year-end 2026 cash to $4.5-$5B.
1. Patent Settlement Details
Moderna agreed to pay up to $2.25 billion to resolve a lipid nanoparticle patent dispute for its COVID-19 vaccine, including a $950 million upfront payment by July 2026 and up to $1.3 billion contingent on appeals.
2. Financial Impact and Liquidity
The $950 million upfront charge reduces Moderna’s projected year-end 2026 cash to $4.5–$5.0 billion, down from prior guidance of $5.5–$6.0 billion, following a $1.873 billion operating cash burn in FY2025.
3. Market Reaction and Sentiment
Shares jumped over 10% in after-hours trading and have climbed 92% year-to-date, while social sentiment scores fell from a quarterly average of 50 to a weekly low of 41 on retail forums.
4. Future Outlook
With a breakeven target set for 2028, Moderna must manage ongoing vaccine R&D, potential contingent payments, and cash controls to extend its liquidity runway and support operations.